Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalfampridine for Gait, Cognition and Fatigue in Egyptian MS Patients
NCT05730738Unknown
- Sponsor
- Ain Shams University
- Start
- Jun 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in multiple sclerosis (MS) comparing dalfampridine with Placebo (2 arms). Primary endpoints: Timed 25-Foot Walk at 3 months, Hauser Ambulation Index at 3 months and 2 more. Status: unknown.
02
Drugs
dalfampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05730738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05730738.